Lasa Supergenerics Valuation

Is LASA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LASA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LASA (₹24.99) is trading above our estimate of fair value (₹2.25)

Significantly Below Fair Value: LASA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LASA?

Key metric: As LASA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LASA. This is calculated by dividing LASA's market cap by their current revenue.
What is LASA's PS Ratio?
PS Ratio	1x
Sales	₹1.22b
Market Cap	₹1.25b

LASA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	86.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LASA's PS Ratio compare to its peers?

The above table shows the PS ratio for LASA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.3x
530233 Auro Laboratories	3.2x	n/a	₹1.2b
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	₹1.6b
540686 Smruthi Organics	1.1x	n/a	₹1.3b
532637 Mangalam Drugs & Organics	0.5x	n/a	₹1.7b
LASA Lasa Supergenerics	1x	n/a	₹1.3b

Price-To-Sales vs Peers: LASA is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does LASA's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.5x	n/a	US$89.21m
539561 Remedium Lifecare	0.07x	n/a	US$28.41m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.04m
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	US$19.22m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: LASA is good value based on its Price-To-Sales Ratio (1x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is LASA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LASA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LASA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7.4%

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

-3.6%

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%